Shares of Targacept Inc. (NASDAQ:CBIO) have received an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Brokers have set a one year consensus target price of $3.50 for the company and are forecasting that the company will post ($0.48) EPS for the current quarter, according to Zacks. Zacks has also assigned Targacept an industry rank of 108 out of 265 based on the ratings given to related companies.
Several equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $3.50 price objective on shares of Targacept in a report on Thursday. Rodman & Renshaw assumed coverage on shares of Targacept in a report on Thursday, June 30th. They issued a “buy” rating and a $3.50 price objective for the company.
Shares of Targacept (NASDAQ:CBIO) opened at 1.19 on Friday. Targacept has a 52-week low of $1.11 and a 52-week high of $6.04. The firm’s market capitalization is $14.08 million. The company has a 50 day moving average of $1.25 and a 200 day moving average of $1.44.
Targacept (NASDAQ:CBIO) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.11. Targacept had a negative return on equity of 62.53% and a negative net margin of 4,155.13%. On average, analysts anticipate that Targacept will post ($1.40) earnings per share for the current fiscal year.
Targacept Company Profile
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Targacept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Targacept Inc. and related companies with MarketBeat.com's FREE daily email newsletter.